Botti C, Negri D R, Seregni E, Ramakrishna V, Arienti F, Maffioli L, Lombardo C, Bogni A, Pascali C, Crippa F, Massaron S, Remonti F, Nerini-Molteni S, Canevari S, Bombardieri E
Nuclear Medicine Department, National Cancer Institute, Milano, Italy.
Eur J Nucl Med. 1997 May;24(5):497-504. doi: 10.1007/BF01267680.
One approach in the treatment of ovarian cancer patients involves the infusion of autologous T lymphocytes coupled with a bispecific monoclonal antibody MOv18/anti-CD3 (biMAb OC/TR), which recognizes a 38-kDa glycoprotein expressed on ovarian carcinomas and the CD3 T cell receptor. However, little is known about the in vivo biodistribution of injected activated lymphocytes, information that could be obtained by scintigraphic imaging of radiolabelled T cells in order to visualize the migratory pattern. We compared the efficiency, stability and toxicity of technetium-99m hexamethylpropylene amine oxime (HMPAO), indium-111 oxine and fluorine-18 2-fluoro-2-deoxy-d-glucose (FDG) in radiolabelling activated lymphocytes targeted with biMAb OC/TR. The mean labelling efficiencies of 111In-oxine and 18F-FDG using 2.5x10(8) lymphocytes (68% and 64%, respectively) were more than twice that of 99mTc-HMPAO (31%). Retention of the radionuclide in the cell was highest in the case of 111In-oxine labelling (less than 25% of the initial cell-bound activity released after 240 min, as compared with 44% of the 99mTc label in the same period and 45% of 18F radionuclide released after 150 min). None of the three radiolabelling reagents induced any significant alteration in cell viability or immunophenotype. However, both 111In-oxine and 18F-FDG induced a loss of cytotoxic activity of lymphocytes against the ovarian carcinoma cell line IGROV1, and all three radiolabelling reagents caused a significant reduction in the proliferative ability of labelled lymphocytes compared to controls, with cell death occurring after 8-9 days. Radiolabelling with the more stable 111In-oxine reagent using a higher number of lymphocytes (1.4x10(9)) but the same total activity (around 55.5 MBq) resulted in improved labelled T cell viability and proliferative ability, although the mean labelling efficiency decreased (35.8%). Together the data suggest that 111In-oxine at low activity per cell is the most appropriate reagent for radiolabelling activated retargeted T lymphocytes useful for in vivo biodistribution studies.
卵巢癌患者的一种治疗方法是输注自体T淋巴细胞,并结合双特异性单克隆抗体MOv18/抗CD3(双特异性抗体OC/TR),该抗体可识别卵巢癌上表达的一种38 kDa糖蛋白和CD3 T细胞受体。然而,对于注射的活化淋巴细胞的体内生物分布了解甚少,而通过放射性标记T细胞的闪烁成像可以获得相关信息,以便观察其迁移模式。我们比较了锝-99m六甲基丙烯胺肟(HMPAO)、铟-111氧嗪和氟-18 2-氟-2-脱氧-D-葡萄糖(FDG)对用双特异性抗体OC/TR靶向的活化淋巴细胞进行放射性标记的效率、稳定性和毒性。使用2.5×10⁸个淋巴细胞时,铟-111氧嗪和氟-18 FDG的平均标记效率(分别为68%和64%)是锝-99m HMPAO(31%)的两倍多。在铟-111氧嗪标记的情况下,放射性核素在细胞内的保留率最高(240分钟后释放的初始细胞结合活性不到25%,同期锝-99m标记释放44%,氟-18放射性核素在150分钟后释放45%)。三种放射性标记试剂均未引起细胞活力或免疫表型的任何显著改变。然而,铟-111氧嗪和氟-18 FDG均导致淋巴细胞对卵巢癌细胞系IGROV1的细胞毒性活性丧失,与对照相比,所有三种放射性标记试剂均导致标记淋巴细胞的增殖能力显著降低,8 - 9天后细胞死亡。使用数量更多的淋巴细胞(1.4×10⁹)但总活性相同(约55.5 MBq),用更稳定的铟-111氧嗪试剂进行放射性标记,虽然平均标记效率降低(35.8%),但标记的T细胞活力和增殖能力得到改善。这些数据共同表明,每个细胞低活性的铟-111氧嗪是用于体内生物分布研究的放射性标记活化重定向T淋巴细胞的最合适试剂。